In patients treated with various EGFR inhibitors, including gefitinib, erlotinib, cetuximab, and panitumumab, low levels of serum IL-8 correlating with stronger EGFR inhibition were also associated with a higher grade of skin toxicity [9]. This evidence concerns the gene CXCL8 and dermatological toxicity.